{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:10:29Z","timestamp":1769717429167,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Cell Therapy Accelerator Program"},{"DOI":"10.13039\/501100000098","name":"Stem Cell Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Latent Epstein\u2013Barr virus (EBV) infection is asymptomatic in most adults but can be associated with lymphoma, particularly in immunocompromised patients. Options are limited for patients with EBV viremia disease refractory to B-cell depleting antibodies or chemotherapy. Cellular therapies targeting EBV have shown promise in treating EBV-associated malignancies and restoring anti-EBV immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a phase I\/II clinical trial in 9 patients, along with 3 additional single-patient trial cases, evaluating patient-specific manufacturing and administration of virus-specific T cells (VSTs) from various sources for the treatment or prevention of EBV-related lymphoma. The VSTs were produced from autologous and allogeneic peripheral blood mononuclear cells (PBMCs) using synthetic viral peptides stimulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three patients were allogeneic hematopoietic stem cell transplant (HCT) recipients, 4 were solid organ transplant (SOT) recipients, and 2 were nontransplant patients with EBV-associated lymphoma. VSTs were successfully manufactured from healthy donors and demonstrated strong and specific reactivity to EBV. Six patients achieved or maintained complete responses (3 SOT and 3 HCT) while 3 did not respond to therapy (1 SOT recipient and 2 nontransplant patients), resulting in an overall response rate of 67% (86% in transplant patients). One patient died of noninfusion related complications during the study follow-up period. Cell infusions were well tolerated with no treatment-related serious adverse events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results strengthen previously published results using VSTs from healthy donors and further support the development of EBV-specific T cell therapies to treat refractory EBV reactivation and EBV-associated malignancies, particularly in transplant recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag006","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:38:08Z","timestamp":1767875888000},"source":"Crossref","is-referenced-by-count":0,"title":["Rapidly Expanded EBV-Specific T Cells for the Treatment of Refractory EBV Reactivation and EBV-Related Lymphoproliferative Disorders"],"prefix":"10.1093","volume":"13","author":[{"given":"Lorne","family":"Schweitzer","sequence":"first","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]},{"name":"Division of Infectious Diseases and Medical Microbiology, Department of Medicine, McGill University Health Centre , Montreal, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Thiant","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Th\u00e9rien","sequence":"additional","affiliation":[{"name":"Centre C3i , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Giroux","sequence":"additional","affiliation":[{"name":"Cell Therapy Laboratory, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Lachance","sequence":"additional","affiliation":[{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Orio","sequence":"additional","affiliation":[{"name":"Centre C3i , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Carli","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Boudreau","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Patenaude","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Tremblay-Lagani\u00e8re","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Sen\u00e9cal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Division of Nephrology, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon F","family":"Dufresne","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]},{"name":"Division of Microbiology and Infectious Diseases, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Microbiology, Infectiology and Immunology, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigina","family":"Mollica","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]},{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzon","family":"Collette","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Division of Nephrology, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kiss","sequence":"additional","affiliation":[{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Cohen","sequence":"additional","affiliation":[{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Bernard","sequence":"additional","affiliation":[{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Bambace","sequence":"additional","affiliation":[{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Veilleux","sequence":"additional","affiliation":[{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]},{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Roy","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]},{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambert","family":"Busque","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]},{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Duval","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Centre hospitalier universitaire Sainte-Justine , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Pediatrics, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique","family":"Bittencourt","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Centre hospitalier universitaire Sainte-Justine , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Pediatrics, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Teira","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Centre hospitalier universitaire Sainte-Justine , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Pediatrics, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-1241","authenticated-orcid":false,"given":"Caroline","family":"Lamarche","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Division of Nephrology, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis-Claude","family":"Roy","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]},{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-7287","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019H\u00f4pital Maisonneuve-Rosemont , Montreal, QC ,","place":["Canada"]},{"name":"Institut Universitaire d\u2019h\u00e9matologie, oncologie et th\u00e9rapie cellulaire, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, QC ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, QC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026012903163439000_ofag006-B1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/v15030714","article-title":"Epstein-Barr Virus history and pathogenesis","volume":"15","author":"Yu","year":"2023","journal-title":"Viruses"},{"key":"2026012903163439000_ofag006-B2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein\u2013Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012903163439000_ofag006-B3","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.2023020075","article-title":"How I treat posttransplant lymphoproliferative disorder","volume":"142","author":"Amengual","year":"2023","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B4","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2021-147307","article-title":"Clinical outcomes of solid organ transplant patients with Epstein-Barr Virus-Driven (EBV +) Post-Transplant Lymphoproliferative Disorder (PTLD) who fail rituximab plus chemotherapy: a Multinational, Retrospective Chart Review Study","volume":"138","author":"Dharnidharka","year":"2021","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"2026012903163439000_ofag006-B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"2026012903163439000_ofag006-B7","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012903163439000_ofag006-B8","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V95.3.807.003k24_807_814","article-title":"Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells","volume":"95","author":"Gustafsson","year":"2000","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B9","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","article-title":"Infusion of autologous Epstein-Barr virus (EBV)\u2013specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication","volume":"99","author":"Comoli","year":"2002","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","article-title":"Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells","volume":"360","author":"Haque","year":"2002","journal-title":"Lancet"},{"key":"2026012903163439000_ofag006-B11","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"key":"2026012903163439000_ofag006-B12","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B14","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B15","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B16","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B17","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B18","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T cells for therapy-resistant disease","volume":"55","author":"Uhlin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026012903163439000_ofag006-B19","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"2026012903163439000_ofag006-B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr Virus (EBV) nuclear antigen 1\u2013specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026012903163439000_ofag006-B21","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CJI.0000000000000031","article-title":"T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I\/II feasibility and safety study","volume":"37","author":"Gallot","year":"2014","journal-title":"J Immunother"},{"key":"2026012903163439000_ofag006-B23","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026012903163439000_ofag006-B24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br J Haematol"},{"key":"2026012903163439000_ofag006-B25","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human Herpesvirus 6, cytomegalovirus, Epstein-Barr Virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026012903163439000_ofag006-B26","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"key":"2026012903163439000_ofag006-B27","doi-asserted-by":"crossref","first-page":"e13133","DOI":"10.1111\/petr.13133","article-title":"Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children","volume":"22","author":"Chiou","year":"2018","journal-title":"Pediatr Transplant"},{"key":"2026012903163439000_ofag006-B28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"key":"2026012903163439000_ofag006-B29","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv"},{"key":"2026012903163439000_ofag006-B30","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ajt.2024.04.009","article-title":"Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant","volume":"24","author":"Khoury","year":"2024","journal-title":"Am J Transplant"},{"key":"2026012903163439000_ofag006-B31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2021-147274","article-title":"Multicenter, open-label, phase 3 study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant recipients with Epstein-Barr Virus-driven post transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE)","volume":"138","author":"Prockop","year":"2021","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B32","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3324\/haematol.2022.281996","article-title":"Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation","volume":"108","author":"Heinz","year":"2023","journal-title":"Haematologica"},{"key":"2026012903163439000_ofag006-B33","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"key":"2026012903163439000_ofag006-B34","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/bloodadvances.2023011562","article-title":"Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients","volume":"8","author":"Dadwal","year":"2024","journal-title":"Blood Adv"},{"key":"2026012903163439000_ofag006-B35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026012903163439000_ofag006-B36","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.3390\/cancers15072133","article-title":"EBV and lymphomagenesis","volume":"15","author":"Sausen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026012903163439000_ofag006-B37","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2024.03.012","article-title":"Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients","volume":"26","author":"Vasileiou","year":"2024","journal-title":"Cytotherapy"},{"key":"2026012903163439000_ofag006-B38","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1097\/TP.0000000000001698","article-title":"Clinical-scale rapid autologous BK virus-specific T cell line generation from kidney transplant recipients with active viremia for adoptive immunotherapy","volume":"101","author":"Lamarche","year":"2017","journal-title":"Transplantation"},{"key":"2026012903163439000_ofag006-B39","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026012903163439000_ofag006-B40","doi-asserted-by":"crossref","first-page":"eado2048","DOI":"10.1126\/sciadv.ado2048","article-title":"Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo","volume":"10","author":"Palianina","year":"2024","journal-title":"Sci Adv"},{"key":"2026012903163439000_ofag006-B41","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/bloodadvances.2022007270","article-title":"Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing","volume":"7","author":"Huisman","year":"2023","journal-title":"Blood Adv"},{"key":"2026012903163439000_ofag006-B42","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"2026012903163439000_ofag006-B43","doi-asserted-by":"crossref","first-page":"e163548","DOI":"10.1172\/JCI163548","article-title":"Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors","volume":"133","author":"Bonifacius","year":"2023","journal-title":"J Clin Invest"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag006\/66423862\/ofag006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/1\/ofag006\/66423862\/ofag006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/1\/ofag006\/66423862\/ofag006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:16:41Z","timestamp":1769674601000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag006\/8426649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag006","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,26]]},"article-number":"ofag006"}}